Skip to main content
Geri

Bu sayfa sadece kayıtlı üyelerimizin erişimine açıktır.

  • Yaklaşan etkinlikler ve web seminerleri, en güncel bilimsel yayınlar ve ürün yeniliklerinden haberdar olun

  • Değerli özelliklerden yararlanın: sesli dinleme, hastalarınızla paylaşılacak materyaller

  • Mesleki bilginizi artırmak için seçkin dermatolojik hizmetlere erişin: +500 patoloji görseli, klinik vaka, uzman videoları

BIODERMA EADV Kongre Raporu Bahar 2023

Dr. Almudena Nuño González (Dermatologist, Spain) ve Dr. Ruzica Jurakić Toncic (Dermatologist, Croatia) tarafından yazılan raporlar.

30 okuma

Report written by Dr. Almudena Nuño González

 

Microbiota and acne

We are learning more and more about the importance of microorganisms that live with us (making up our microbiota), and in relation to skin, among the most studied microorganisms are acne bacteria. In the case of acne, both the skin and intestinal microbiota are altered. In the skin microbiome, IA-type Cutibacterium acnes feeds off of sebum and is more inflammatory than other types of acne bacteria. Biodiversity is lost in the microbiome in favour of this bacterium. In addition, the involvement of Malasezzia has been found in some cases. With regard to the intestinal microbiome, acne has been associated with cases of intestinal permeability and excessive bacterial growth. There are studies suggesting it can be beneficial to give probiotics in these cases.

 

Acne in adult women

Above all, adult acne predominates among women, representing 82.1% of cases, with men only making up 17.9% of cases. It is unknown if cases of adult acne are actually increasing or if patients are just now consulting dermatologists more often. It appears that the pathogenesis of adult acne is different from that of adolescent acne: multiple factors are involved, including stress, diet, changes in sebaceous secretion, medication, smoking, endocrine disorders, and more, in addition to a genetic predisposition.

With regard to associated endocrine disorders, polycystic ovary syndrome is the most common in women of reproductive age: 6 to 10% of women live with this condition, and among those women, 42% have acne. It is more common for acne to recur in these cases after dermatological treatment and it typically affects the lower portion of the face. In all of these patients, we must investigate if there is any hormonal alteration associated with acne fulminans, characterised by ulceronecrotic lesions, scabs, and scarring.

 

Severe forms of acne

Acne fulminans is a severe form of acne with several differences in comparison to acne conglobata. Acne fulminans occurs more suddenly and mainly during adolescence, while acne conglobata occurs more often in adults and does not begin as abruptly. Both are associated with androgens. These conditions should be treated with corticosteroids and isotretinoin. However, isotretinoin has been associated with the appearance of acne fulminans, in which case isotretinoin treatment should cease and be replaced with corticosteroids. Once the patient is stabilised, isotretinoin treatment can start again at low doses. This type of pathology can be associated with systemic symptoms such as fever, arthralgia, and leukocytosis, but not in all cases.

Other types of severe acne are associated with autoinflammatory diseases, such as PAPA, PAPASH, PASH, PASS, and SAPHO. Such severe cases are treated with biologics such as anakinra, ustekinumab, and secukinumab.

 

Advancements in the treatment of acne

New treatments for acne are emerging.

  • Minocycline topical foam 4% showed improvement for 30% of patients, versus 19% for the foam vehicle group in the study.
  • Microencapsulated benzoyl peroxide 3% + tretinoin 0.1%: with silica-based gel that enables deferred release. Thanks to the formulation and vehicle, there are virtually no side effects.
  • Clascoterone 1%: first new mechanism in many years. It is an androgen receptor inhibitor, thus blocking the release of sebum and proinflammatory cytokines such as IL-1, IL-6, and TNF-alpha. However, the results are not very compelling, with improvement for 20% of patients, versus 8.8% for the vehicle group in studies. It is being sold in the United States, but it is not yet available in Europe.
  • Spironolactone is used not only for treatment of acne, but also for HS and androgenetic alopecia. It is particularly used for women aged 19 years and older. What’s new is topical spironolactone. In studies, it diminished comedones and inflammatory lesions. (In one study of topical spironolactone 2% versus topical clindamycin 1.5%, the spironolactone demonstrated greater efficacy. Other concentrations go up to 5%. More studies are needed.)
  • Additionally, spironolactone has anti-acne effects up to months after its use has ended.
  • N-Acetyl-GED-0507-34-LEVO gel in patients with moderate to severe acne: The first topical combination of three products: clindamycin, benzoyl peroxide, and adapalene. Available soon. In studies, over 50% of patients (52.5%) achieved satisfactory results at 12 weeks. It appears to be the most effective topical treatment (current topical treatments achieve efficacy in at most 40% of cases).
  • Probiotics in the treatment of acne: for treatment of C. acnes, taken both orally, with lactobacillus, and topically to regulate sebaceous secretion from the sebaceous glands. More studies are needed.

Ask NAOS Pro veri gizliliğini ve güvenliğini önemsemektedir
Bu web sitesi çerez kullanır ve etkinleştirmek istediğiniz çerezleri kontrol etmenizi sağlar.